Advanced search
Publication Cover
Hematology Volume 27, 2022 - Issue 1
Submit an article Journal homepage
2,136
Views
1
CrossRef citations to date
0
Altmetric
Case Report

De novo lymphoid blastic phase chronic myeloid leukemia: report and contemporary discussion

Maha Hameeda College of Medicine, Alfaisal University, Riyadh, Saudi Arabia
,
Mohammed Alnoamanib Department of Hematology, King Fahad Medical City, Riyadh, Saudi Arabia
,
Mohammed Mareib Department of Hematology, King Fahad Medical City, Riyadh, Saudi Arabia
,
Imran Tailorb Department of Hematology, King Fahad Medical City, Riyadh, Saudi Arabia
,
Hassan Alshehrib Department of Hematology, King Fahad Medical City, Riyadh, Saudi Arabia
,
Soha A. Tashkandic Cytogenetics Laboratory, Department of Clinical Pathology, King Fahad Medical City, Riyadh, Saudi Arabia
,
Azizah Alswayyedc Cytogenetics Laboratory, Department of Clinical Pathology, King Fahad Medical City, Riyadh, Saudi Arabia
,
Abdullah M. Alrajhid Department of Clinical Pharmacy, King Fahad Medical City, Riyadh, Saudi Arabia;e Department of Pharmacy Practice, College of Pharmacy, AlFaisal University, Riyadh, Saudi Arabia
,
Syed Z. A. Zaidib Department of Hematology, King Fahad Medical City, Riyadh, Saudi Arabia
,
Ibraheem Motabib Department of Hematology, King Fahad Medical City, Riyadh, Saudi Arabia
,
Nawal AlShehryb Department of Hematology, King Fahad Medical City, Riyadh, Saudi Arabia
&
Mansour Alfayeza College of Medicine, Alfaisal University, Riyadh, Saudi Arabia;b Department of Hematology, King Fahad Medical City, Riyadh, Saudi Arabia;f Oncology Centre, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi ArabiaCorrespondence[email protected] [email protected]
 show all
Pages 1259-1262 | Received 22 Apr 2022, Accepted 14 Nov 2022, Published online: 30 Nov 2022

References

  • Jabbour E, Kantarjian H, O'Brien S, et al. Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood. Jan 2006;107(2):480–482. doi:10.1182/blood-2005-05-1816.
  • Alfayez M, Richard-Carpentier G, Jabbour E, et al. Sudden blastic transformation in treatment-free remission chronic myeloid leukaemia. Br J Haematol. 2019;187(4):543–545.
  • Ohanian M, Kantarjian HM, Quintas-Cardama A, et al. The clinical impact of time to response in De Novo accelerated phase chronic myeloid leukemia (CML-AP). Blood. 2012;120(21):72–72. doi:10.1182/blood.V120.21.72.72.
  • Hovorkova L, Zaliova M, Venn NC, et al. Monitoring of childhood ALL using. Blood. 2017;129(20):2771–2781. doi:10.1182/blood-2016-11-749978.
  • Sloma I, Jiang X, Eaves AC, et al. Insights into the stem cells of chronic myeloid leukemia. Leukemia. Nov 2010;24(11):1823–1833. doi:10.1038/leu.2010.159.
  • Sasaki K, Jabbour EJ, Ravandi F, et al. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2016;122(23):3650–3656. doi:10.1002/cncr.30231.
  • Jabbour E, Sasaki K, Short NJ, et al. Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. 2021;127(12):2025–2038. doi:10.1002/cncr.33469.
  • Short NJ, Jabbour E, Sasaki K, et al. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2016;128(4):504–507. doi:10.1182/blood-2016-03-707562.
  • Short NJ, Kantarjian H, Jabbour E. Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms. Leukemia. 11 2021;35(11):3044–3058. doi:10.1038/s41375-021-01277-3.
  • Sasaki K, Kantarjian HM, Short NJ, et al. Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer. 2021;127(15):2648–2656. doi:10.1002/cncr.33529.
  • Short NJ, Kantarjian H, Konopleva M, et al. Updated results of a phase II study of ponatinib and blinatumomab for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2021;138(Supplement 1):2298–2298. doi:10.1182/blood-2021-153795.
  • Foà R, Bassan R, Vitale A, et al. Dasatinib-Blinatumomab for Ph-positive acute lymphoblastic leukemia in adults. N Engl J Med. 2020;383(17):1613–1623. doi:10.1056/NEJMoa2016272.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.